攝護腺癌荷爾蒙治療與5α-還原酶抑制劑之使用分析

柳瑞明1, 莊恆彰1, 吳俊德2 許仁駿3

1衛生福利部桃園醫院 泌尿科;2長庚醫療財團法人基隆長庚紀念醫院 泌尿科; 3佛教慈濟醫療財團法人花蓮慈濟醫院 癌症研究中心


Association Between 5α-Reductase Inhibitors and Androgen Deprivation Therapy

 Jui-Ming Liu1, Heng-Chang Chuang1, Chun-Te Wu2 Ren-Jun Hsu 3

1Division of Urology, Department of Surgery Taoyuan General Hospital, Ministry of Health and Welfare

2 Department of Urology, Chang Gung Memorial Hospital, Keelung, Taiwan

3 Cancer Medicine Center of Buddhist Hualien Tzu Chi Hospital, Tzu Chi University, Hualien, Taiwan

 

Background:

Androgen deprivation therapy (ADT) is widely used in advanced prostate cancer. To test the impact of 5α-reductase inhibitors(5-ARIs) on ADT users.

Methods:

We used data from the National Health Insurance Research Database of Taiwan between 1997 and 2016. The study subjects were divided into 5-ARIs users and non-user controls. The demographic characteristics and comorbidities were used t test. Cox proportional hazards regression was used to calculate the hazard ratios (HR) for the risk of thyroid diseases.

Results:

There were 44,566 patients who received ADT. Of those patients, 3,332 patients were 5-ARIs users and 35,489 were non-users. Compared with non-users, 5-ARIs users showed no increased risk of all-cause mortality (hazard ratio [HR]: 0.96; 95% confidence interval [CI]: 0.89–1.04)

Conclusions:

The 5-ARIs were not increase risk of mortality in patients received ADT. Further studies are warranted to have fully investigation.

    位置
    資料夾名稱
    摘要
    發表人
    TUA人資客服組
    單位
    台灣泌尿科醫學會
    建立
    2022-06-07 14:25:09
    最近修訂
    2022-06-07 14:25:40
    更多